A recombinant human interferon-alpha B/D hybrid with a broad host-range.

Area of Science:

• Biochemistry
• Virology
• Immunology

Background:

• Interferons (IFNs) are crucial cytokines with antiviral properties.
• Developing broad-spectrum antiviral agents remains a significant challenge in medicine.
• Recombinant DNA technology allows for the engineering of novel IFN variants with improved characteristics.

Purpose of the Study:

• To characterize the antiviral activity and host-range of a novel human interferon-alpha B/D (HuIFN-alpha B/D) hybrid.
• To compare the efficacy of the HuIFN-alpha B/D hybrid with its parental molecules (HuIFN-alpha B and HuIFN-alpha D) and another IFN variant (HuIFN-alpha F).
• To assess the potential of the engineered IFN hybrid as a broad-spectrum antiviral therapeutic.

Main Methods:

• Construction of a recombinant hybrid interferon comprising amino acids 1-60 of HuIFN-alpha B and amino acids 61-166 of HuIFN-alpha D.
• Antiviral assay using plaque reduction of vesicular stomatitis virus (VSV) in at least 12 different animal cell species.
• Comparative analysis of the cross-species antiviral activity of the hybrid IFN against parental IFNs and HuIFN-alpha F.

Main Results:

• The HuIFN-alpha B/D hybrid exhibited broad host-range antiviral activity.
• The hybrid demonstrated high efficacy in at least 12 animal cell species.
• In cell species where both parental IFNs were active, the hybrid showed comparable or superior activity to the more potent parent.
• The hybrid was significantly more potent than HuIFN-alpha D in human (10-fold), rabbit (30-fold), and mouse (50-fold) cells.
• The hybrid shared broad cross-species activity with HuIFN-alpha D.

Conclusions:

• The engineered HuIFN-alpha B/D hybrid possesses potent and broad-spectrum antiviral activity.
• This IFN hybrid represents a promising candidate for the development of novel antiviral therapies.
• The study highlights the potential of protein engineering to enhance the therapeutic properties of interferons.